Stereotactic Body Radiotherapy in Bulky Hepatocellular Carcinoma with or without Portal Vein Thrombosis: A Feasibility Review in an Egyptian Cohort

被引:0
|
作者
Hegazy, Mohamed Wahba [1 ]
Attallah, Hany [2 ]
El-Shahat, Khaled M. [3 ]
Mostafa, Emad [4 ]
Yassin, Adel [3 ]
Haggag, Ibraheem [4 ]
Fathy, Talaat [5 ]
Monem, Sameh M. Abdel [5 ]
Abdelmoaty, Ahmed [5 ]
Bessar, Ahmed A. [6 ]
机构
[1] Med Coll, Dept Clin Oncol & Nucl Med, Zagazig, Egypt
[2] Int Med Ctr IMC, Dept Radiat Oncol, Cairo, Egypt
[3] Al Azhar Coll Med, Dept Clin Oncol, Cairo, Egypt
[4] Int Med Ctr, Med Radiat Phys, Cairo, Egypt
[5] Coll Med, Trop Dept, Zagazig, Egypt
[6] Coll Med, Radiol Dept, Zagazig, Egypt
关键词
Stereotactic; Hepatocellular; Portal; Veins; Thrombosis; RADIATION-THERAPY; LIVER TOXICITY;
D O I
10.30476/mejc.2023.98866.1918
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hepatocellular carcinoma (HCC) complicated by portal vein thrombosis presents significant clinical challenges. This study aims to retrospectively assess the feasibility of stereotactic irradiation for treating bulky HCC, with or without vascular invasion. Method: In this retrospective analysis, the radiotherapy treatment plans and clinical follow-up data of 22 patients diagnosed with HCC, with or without portal vein thrombosis, were reviewed. These patients underwent stereotactic body radiation therapy (SBRT) between September 2019 and September 2022. Treatment involved administering 40-50 Gy in 5 fractions using SBRT with volumetric modulated arc therapy (VMAT)/4D-computed tomography. Descriptive statistics were utilized without the application of statistical tests. Results: The mean age of the patients was 65 years, with 77% being male. Portal vein thrombosis was present in 73% of the cases, and the average tumor size was 7.2 cm (range 5-12 cm). 59% of patients were classified as Child -Pugh B. The median follow-up duration was 8 months (range 3-36 months). At 3 months, tumor response assessments revealed that 59% of patients had a partial response and 41% had stable disease; by 6 months, 37% achieved complete response, 26% maintained a partial response, and 37% had stable condition. Failure patterns included intrahepatic failure in two patients (at 7 and 9 months) and extrahepatic loss in two others (at 6 and 10 months). Radiation -induced liver disease occurred in two patients at 9- and 11 -weeks posttreatment, respectively. Liver cancer -specific mortality was 13.6%, while non -liver cancer -specific mortality stood at 9%. The progression -free survival rate was 82%. Conclusion: SBRT via VMAT represents a highly cost-effective, non-invasive local therapy with a favorable therapeutic ratio for treating bulky HCC cases, with or without vascular invasion.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 50 条
  • [21] A Preliminary Analysis of Robotic Radiosurgery Stereotactic Body Radiation Therapy With or Without Sorafenib for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
    Que, J. Y.
    Lin, L. C.
    Lin, C. H.
    Lin, K. L.
    Lin, Y. W.
    Yang, C. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E180 - E180
  • [22] Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis
    Kulik, Laura M.
    Carr, Brian I.
    Mulcahy, Mary F.
    Lewandowski, Robert J.
    Atassi, Bassel
    Ryu, Robert K.
    Sato, Kent T.
    Benson, Al, III
    Nemcek, Albert A., Jr.
    Gates, Vanessa L.
    Abecassis, Michael
    Omary, Reed A.
    Salem, Riad
    HEPATOLOGY, 2008, 47 (01) : 71 - 81
  • [23] Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis
    Jeong Il Yu
    Hee Chul Park
    World Journal of Gastroenterology, 2016, (30) : 6851 - 6863
  • [24] Role of radiotherapy in treatment of portal vein thrombosis from hepatocellular carcinoma
    Kim, J. H.
    Kim, C. E. K.
    Ahn, S. D.
    Lee, S. W.
    Shin, S. S.
    Lim, Y. S.
    Chung, Y. W.
    Lee, Y. S.
    EJC SUPPLEMENTS, 2005, 3 (02): : 208 - 208
  • [25] Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis
    Yu, Jeong Il
    Park, Hee Chul
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (30) : 6851 - 6863
  • [26] Preoperative Stereotactic Body Radiotherapy to Portal Vein Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis
    Kishi, Noriko
    Kanayama, Naoyuki
    Hirata, Takero
    Ohira, Shingo
    Wada, Kentaro
    Kawaguchi, Yoshifumi
    Konishi, Koji
    Nagata, Shigenori
    Nakatsuka, Shin-ichi
    Marubashi, Shigeru
    Tomokuni, Akira
    Wada, Hiroshi
    Kobayashi, Shogo
    Tomita, Yasuhiko
    Teshima, Teruki
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [27] Preoperative Stereotactic Body Radiotherapy to Portal Vein Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis
    Noriko Kishi
    Naoyuki Kanayama
    Takero Hirata
    Shingo Ohira
    Kentaro Wada
    Yoshifumi Kawaguchi
    Koji Konishi
    Shigenori Nagata
    Shin-ichi Nakatsuka
    Shigeru Marubashi
    Akira Tomokuni
    Hiroshi Wada
    Shogo Kobayashi
    Yasuhiko Tomita
    Teruki Teshima
    Scientific Reports, 10
  • [28] Stereotactic radiosurgery for palliative management of hepatocellular carcinoma associated with portal vein thrombosis
    AbdelKarim, K.
    Hamed, W.
    ElGharib, M.
    Esmat, G.
    Darwish, M.
    Elebrashi, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S270 - S270
  • [29] PIVKA-II as a tumor marker in hepatocellular carcinoma with and without portal vein thrombosis among Egyptian patients
    Sharaf-Eldin, M.
    Hilmy, A.
    El-Batae, H.
    El Kassas, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 138 - 138
  • [30] Chemoembolization for Unresectable HepatoCellular Carcinoma in Patients with or without Portal Vein Thrombosis
    Carr, Brian I.
    Irish, William
    Federle, Michael P.
    HEPATO-GASTROENTEROLOGY, 2010, 57 (104) : 1375 - 1381